These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 33028340)

  • 1. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM; Calleo VJ; Sullivan RW
    Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
    Dunn KE; Tompkins DA; Bigelow GE; Strain EC
    JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
    D'Onofrio G; Herring AA; Perrone J; Hawk K; Samuels EA; Cowan E; Anderson E; McCormack R; Huntley K; Owens P; Martel S; Schactman M; Lofwall MR; Walsh SL; Dziura J; Fiellin DA
    JAMA Netw Open; 2024 Jul; 7(7):e2420702. PubMed ID: 38976265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan.
    Chambers A; Patton J; Wills BK
    Am J Emerg Med; 2024 May; 79():230.e1-230.e2. PubMed ID: 38556414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naltrexone shortened opioid detoxification with buprenorphine.
    Umbricht A; Montoya ID; Hoover DR; Demuth KL; Chiang CT; Preston KL
    Drug Alcohol Depend; 1999 Oct; 56(3):181-90. PubMed ID: 10529020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone.
    Mannelli P; Douaihy AB; Zavod A; Legedza A; Akerman SC; Sullivan MA
    Am J Drug Alcohol Abuse; 2021 Nov; 47(6):753-759. PubMed ID: 34752714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Maintenance Therapeutic for Opioid Use Disorder.
    Youngblood B; Li K; Gehlert DR; Medina JC; Schwartz N
    J Pharmacol Exp Ther; 2021 Aug; 378(2):133-145. PubMed ID: 34011529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Opioid Use Disorder Treatment With Alcohol-Related Acute Events.
    Xu KY; Presnall N; Mintz CM; Borodovsky JT; Bhat NR; Bierut LJ; Grucza RA
    JAMA Netw Open; 2021 Feb; 4(2):e210061. PubMed ID: 33625511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
    Collins ED; Kleber HD; Whittington RA; Heitler NE
    JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: A case report.
    Ward HB; Barnett BS; Suzuki J
    Subst Abus; 2019; 40(2):140-145. PubMed ID: 30888254
    [No Abstract]   [Full Text] [Related]  

  • 14. Precipitated Opioid Withdrawal Treated With Ketamine in a Hospitalized Patient: A Case Report.
    Christian NJ; Butner JL; Evarts MS; Weimer MB
    J Addict Med; 2023 Jul-Aug 01; 17(4):488-490. PubMed ID: 37579118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl.
    Thakrar AP; Christine PJ; Siaw-Asamoah A; Spadaro A; Faude S; Snider CK; Delgado MK; Lowenstein M; Kampman K; Perrone J; Nelson LS; Kilaru AS
    JAMA Netw Open; 2024 Sep; 7(9):e2435895. PubMed ID: 39331392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods of detoxification and their role in treating patients with opioid dependence.
    O'Connor PG
    JAMA; 2005 Aug; 294(8):961-3. PubMed ID: 16118388
    [No Abstract]   [Full Text] [Related]  

  • 17. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
    Cisewski DH; Santos C; Koyfman A; Long B
    Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suspected Buprenorphine-Precipitated Opioid Withdrawal following Intercourse: A Case Report.
    Lynch D; Chitty L; Johnson B; Hoefnagel AL
    J Pain Palliat Care Pharmacother; 2023 Dec; 37(4):314-316. PubMed ID: 37640398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation.
    Brogdon H; Facer KL; Cox EJ; Carlson RH; Wurzel JF
    J Addict Med; 2022 Jul-Aug 01; 16(4):488-491. PubMed ID: 34864786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.